The oncofetal antigen 5T4 is expressed in many solid tumors, making it an attractive antitumor target. XB010 is a novel, 5T4-targeted, antibody–drug conjugate developed using the SMARTag platform to optimize tolerability. We describe the development, design, and preclinical characterization of XB010. In vitro and in vivo efficacy of XB010 was assessed in cell-derived xenograft breast cancer cell lines (MCF-7 and MDA-MB-468) and in patient-derived xenograft tumor models (squamous cell carcinoma of the head and neck, non–small cell lung cancer, and breast cancer). Additionally, the in vivo combinatorial efficacy of XB010 + anti–PD-1 antibody was assessed in an MC38-h5T4 syngeneic colon cancer xenograft model. The toxicity profile of XB010 was evaluated in both Sprague–Dawley rats and cynomolgus monkeys. XB010 demonstrated in vitro cytotoxic effects with sub-nanomolar potency in the MCF-7 and MDA-MB-468 breast cancer cell lines and in vivo tumor growth inhibition (80%–99%) compared with vehicle-treated animals in xenograft and patient-derived xenograft models at doses of 5 to 10 mg/kg XB010. In the syngeneic MC38-h5T4–expressing colon cancer xenograft model, XB010 + anti–PD-1 showed improved efficacy compared with either agent administered alone. XB010 safety assessments demonstrated tolerability of doses up to 60 mg/kg in rats and up to 25 mg/kg in nonhuman primates. XB010 is a novel anti-5T4 antibody–drug conjugate that exhibits potent antitumor activity, inhibiting cancer cell growth in vitro and tumor growth in various in vivo models, with an acceptable toxicity profile. These findings support the evaluation of XB010 in clinical studies.
In vivo tumor growth inhibition and survival curves following intravenous administration of XB010 in (A–D) the MCF-7 xenograft model and in vivo tumor growth inhibition in the (E) MDA-MB-468 murine breast cancer xenograft model. Dose–response study with either (A) a single dose or (B) once weekly x2 dosing of XB010 in the MCF-7 model. Survival curves for (C) single dose and (D) once weekly x2 dose studies. XB010 led to dose-related tumor volume suppression and longer survival (right-shifted curves) compared with vehicle following either dosing regimen. As shown in (E), XB010 produced maximal and durable suppression starting at 20 days after dose in the MDA-MB-468 model. Survival curves were not generated for this study as only two of eight animals in the vehicle reached the prespecified survival outcome.
Figure S7: TK profile of XB010 in rats. Following single IV doses of XB010 (30, 60, and 90 mg/kg) administered to female Sprague Dawley rats, linear TK profiles were observed over 11 days. Near-identical TK profiles were observed for the total antibody and total ADC, demonstrating the stability of XB010.
Cytotoxic activity of XB010 in (A) MCF-7 and (B) MDA-MB-468 breast cancer cell lines. XB010-mediated in vitro cytotoxicity was observed in both tumor cell lines that were used for in vivo xenograft studies. In both cell lines, XB010 demonstrated improved potency and similar maximal inhibition compared with the positive control (5T4-targeting mafodotin ADC). Conc, concentration.
Figure S8: TK profile of XB010 in NHPs. Following repeat IV doses of XB010 (1, 6, and 25 mg/kg) administered to NHPs on days 1 and 22, non-linear TK profiles were observed, indicating target-mediated drug disposition. XB010 was stable in NHPs, with nearly identical TK profiles for the total antibody and total ADC, and low levels of unconjugated MMAE.